Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$38 Mln
Revenue (TTM)
$142 Mln
Net Profit (TTM)
$0 Mln
ROE
-8.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
12
Industry P/E
--
EV/EBITDA
-1.9
Div. Yield
0 %
Debt to Equity
-0.8
Book Value
$--
EPS
$-1
Face value
--
Shares outstanding
8,639,900
CFO
$-1,163.15 Mln
EBITDA
$-1,329.38 Mln
Net Profit
$-1,439.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
| 563.9 | -2.2 | -30.1 | 360.3 | -4.3 | -25.6 | -16.8 |
|
BSE Sensex
| 4.9 | 0.4 | 6.7 | 6.3 | 16.2 | 18.3 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
| -21.7 | -74.6 | -47.1 | -58.5 | -19.2 | 104.6 | -2.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
4.5 | 38.4 | 142.1 | -62.5 | -5.3 | -- | -- | 12.0 |
| 49.8 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.2 | 8,290.2 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.2 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.2 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 44.9 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 53.9 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 313.5 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 4.9 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers,... develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. Address: 85 Wells Avenue, Newton, MA, United States, 02459-3298 Read more
President, CEO & Director
Mr. Richard A. Paulson M.B.A.
President, CEO & Director
Mr. Richard A. Paulson M.B.A.
Headquarters
Newton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Karyopharm Therapeutics Inc (KPTI) stood at $ 218 Mln as on 31-Mar-25
The share price of Karyopharm Therapeutics Inc (KPTI) is $4.49 (NASDAQ) as of 24-Jun-2025 12:34 EDT. Karyopharm Therapeutics Inc (KPTI) has given a return of -4.34% in the last 3 years.
Karyopharm Therapeutics Inc (KPTI) has a market capitalisation of $ 38 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Karyopharm Therapeutics Inc (KPTI) is 12.05 times as on 23-Jun-2025, a 332% premium to its peers’ median range of 2.79 times.
Since, TTM earnings of Karyopharm Therapeutics Inc (KPTI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Karyopharm Therapeutics Inc (KPTI) and enter the required number of quantities and click on buy to purchase the shares of Karyopharm Therapeutics Inc (KPTI).
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. Address: 85 Wells Avenue, Newton, MA, United States, 02459-3298
The CEO & director of Mr. Richard A. Paulson M.B.A.. is Karyopharm Therapeutics Inc (KPTI), and CFO & Sr. VP is Mr. Richard A. Paulson M.B.A..
There is no promoter pledging in Karyopharm Therapeutics Inc (KPTI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Karyopharm Therapeutics Inc. (KPTI) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-5.3
|
|
Net Margin(%)
|
-43.99
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Karyopharm Therapeutics Inc (KPTI) was $0 Mln.
$0.16
(
